Summary
At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory diseases were considered to be at high risk for SARS-CoV-2 infection and the development of severe COVID-19. Data collected over the past year, however, suggest that a diagnosis of inflammatory arthritis, psoriasis, or inflammatory bowel diseases does not increase risk for SARS-CoV-2 infection or severe COVID-19 compared with people without these diseases. Furthermore, substantial data suggest that certain medications frequently used in patients with immune-mediated inflammatory diseases, in particular cytokine inhibitors, might even lower the risk for severe COVID-19. Conversely, glucocorticoids and potentially B-cell-depleting treatments seem to worsen COVID-19 outcomes. Additionally, the first data on SARS-CoV-2 vaccination in patients with these diseases suggest that tolerability of vaccination in patients with immune-mediated inflammatory diseases is good, although the immune response to vaccination can be somewhat reduced in this patient group, particularly those taking methotrexate or CD20-targeted treatment.
【초록키워드】 COVID-19, Treatment, immune response, vaccination, Diseases, severe COVID-19, SARS-COV-2 infection, COVID-19 pandemic, Diagnosis, risk, glucocorticoid, Inflammatory bowel disease, outcomes, Patient, Inflammatory arthritis, methotrexate, medication, disease, SARS-CoV-2 vaccination, high risk, Tolerability, Immune-mediated inflammatory diseases, cytokine inhibitors, Immune-mediated inflammatory disease, collected, reduced, 【제목키워드】 COVID-19, Treatment, outcome, vaccine response, disease, Immune-mediated, Inflammatory,